Lung Cancer Screening : Refined
Averywell revolutionizes early lung cancer detection and lung nodule management with a groundbreaking miRNA-based liquid biopsy. Our non-invasive, precise, and cost-effective technology ensures early detection, enabling timely treatment access for smokers and non-smokers.
Innovative Detection
Early Intervention
Non-Invasive Technology
Comprehensive Strategy
Our Mission
Your Health, Our Priority
Our mission is to revolutionize lung cancer detection and prevention. We are dedicated to make lung cancer testing highly reliable, convenient, and accessible through a simple blood test.
By harnessing the power of early detection, our primary goal is to make a substantial impact by significantly reducing the number of avoidable deaths attributed to lung cancer. We firmly believe that no one should have to endure the devastating consequences of a late-stage diagnosis. Our commitment is to equip individuals with the essential tools needed to detect and treat this formidable disease in its earliest, most treatable stages.
We envision a world where lung cancer ceases to be a leading cause of cancer-related deaths, and it is through our unwavering mission that we strive to transform this vision into a reality
New cases of Lung Cancer
Deaths from Lung Cancer
%
Survive Lung Cancer for more than 10 years
%
Lung Cancer cases are preventable
Empowering Patients through Early Detection
Averywell’s mission is to empower patients through early detection, providing them with timely access to appropriate treatments. Our revolutionary screening approach significantly enhances survival rates and improves patient outcomes. We understand the importance of early detection in the context of lung cancer and discuss the broader implications for individuals facing this diagnosis.
Equitable Screening for Smokers and Non-Smokers
Our miRNA-based liquid biopsy technology is designed to be inclusive, catering to both smokers and non-smokers. Ensuring equitable screening for all at-risk individuals is a key aspect of Averywell’s approach. The inclusivity of our screening test and its potential to bridge gaps in lung cancer detection, contributes to a more comprehensive and accessible screening strategy.
Addressing Economic and Social Burdens
Averywell’s solution goes beyond clinical benefits by addressing economic and social burdens associated with lung cancer. Our innovative approach stands out amid overlapping symptoms and presents a compelling response to the unique challenges posed by the pandemic. We aim to alleviate burdens and offer hope for reduced healthcare costs and improved quality of life for patients and their families.
Harnessing the Power of Early Detection to Reduce Avoidable Deaths…
A Commitment to Early Detection.
Cutting-Edge and Transformative
Our Technology
The convergence of cutting-edge technology and transformative healthcare solutions defines Averywell’s commitment to revolutionizing medical diagnostics. Our state-of-the-art microRNA technology represents a paradigm shift, seamlessly integrating AI and machine learning into our revolutionary miRNA liquid biopsy approach.
By leveraging artificial intelligence in the analysis of microRNA profiles, we have achieved unprecedented accuracy and efficiency in cancer detection. This pioneering fusion enhances diagnostic precision and enables early identification, empowering healthcare professionals with proactive and tailored treatment strategies.
Supported By:
